company background image
NECLIFE logo

Nectar Lifesciences NSEI:NECLIFE Stock Report

Last Price

₹41.94

Market Cap

₹9.4b

7D

2.4%

1Y

74.0%

Updated

04 Oct, 2024

Data

Company Financials

Nectar Lifesciences Limited

NSEI:NECLIFE Stock Report

Market Cap: ₹9.4b

Nectar Lifesciences Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nectar Lifesciences
Historical stock prices
Current Share Price₹41.94
52 Week High₹56.50
52 Week Low₹21.50
Beta1.01
11 Month Change4.69%
3 Month Change33.14%
1 Year Change74.02%
33 Year Change31.06%
5 Year Change252.44%
Change since IPO61.25%

Recent News & Updates

Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth

Aug 22
Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth

Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden

Jul 27
Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden

Recent updates

Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth

Aug 22
Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth

Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden

Jul 27
Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden

Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Feb 19
Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

Dec 22
Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?

Jun 16
Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?

Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Jun 21
Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Jul 29
Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Is Nectar Lifesciences Limited (NSE:NECLIFE) A Risky Dividend Stock?

Feb 25
Is Nectar Lifesciences Limited (NSE:NECLIFE) A Risky Dividend Stock?

Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet

Jan 21
Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet

Zooming in on NSE:NECLIFE's 0.3% Dividend Yield

Nov 02
Zooming in on NSE:NECLIFE's 0.3% Dividend Yield

Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

Sep 07
Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today

Aug 09
If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today

The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More

Aug 09
The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More

What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E

Jul 13
What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E

Shareholder Returns

NECLIFEIN PharmaceuticalsIN Market
7D2.4%-0.4%-2.6%
1Y74.0%60.6%42.2%

Return vs Industry: NECLIFE exceeded the Indian Pharmaceuticals industry which returned 60.6% over the past year.

Return vs Market: NECLIFE exceeded the Indian Market which returned 42.2% over the past year.

Price Volatility

Is NECLIFE's price volatile compared to industry and market?
NECLIFE volatility
NECLIFE Average Weekly Movement9.6%
Pharmaceuticals Industry Average Movement6.1%
Market Average Movement6.2%
10% most volatile stocks in IN Market9.3%
10% least volatile stocks in IN Market3.9%

Stable Share Price: NECLIFE's share price has been volatile over the past 3 months compared to the Indian market.

Volatility Over Time: NECLIFE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company

FoundedEmployeesCEOWebsite
19951,686Amit Chadahwww.neclife.com

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company’s active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins.

Nectar Lifesciences Limited Fundamentals Summary

How do Nectar Lifesciences's earnings and revenue compare to its market cap?
NECLIFE fundamental statistics
Market cap₹9.41b
Earnings (TTM)₹61.44m
Revenue (TTM)₹16.49b

153.1x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NECLIFE income statement (TTM)
Revenue₹16.49b
Cost of Revenue₹11.60b
Gross Profit₹4.89b
Other Expenses₹4.83b
Earnings₹61.44m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.27
Gross Margin29.64%
Net Profit Margin0.37%
Debt/Equity Ratio59.4%

How did NECLIFE perform over the long term?

See historical performance and comparison